BAY1161909

pro-mitotic selective MPS1 kinase inhibitor

dev. paused for 2nd candidate (BAY1217389)

from 2M cmpd biochem. HTS and SBDD

J. Med. Chem., Apr. 27, 2020

Bayer AG, Berlin, DE

BAY1161909 is one of two clinical candidates disclosed in a single paper from Bayer. The compounds have an interesting anti-cancer mechanism – rather than inhibiting cancer cell growth, they accelerate…


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.